Search Results - Levy, Elliott

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study

    Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study by Lampert, Erika J., Zimmer, Alexandra, Padget, Michelle, Cimino-Mathews, Ashley, Nair, Jayakumar, Liu, Yingmiao, Swisher, Elizabeth M., Hodge, James W., Nixon, Andrew B., Nichols, Erin, Bagheri, Mohammad H., Levy, Elliott, Radke, Marc R., Lipkowitz, Stanley, Annunziata, Christina M., Taube, Janis M., Steinberg, Seth M., Lee, Jung-Min

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: